<DOC>
	<DOCNO>NCT00821691</DOCNO>
	<brief_summary>The objective study test action amantadine , DOPA-agonist , double blind cross-over trial , amantadine / placebo , verbal fluency chronic post stroke aphasic patient .</brief_summary>
	<brief_title>Action Amantadine Post-Stroke Aphasic Patients</brief_title>
	<detailed_description>In France , around 30000 aphasic patient . The actual taking care patient stroke include treatment acute stage stroke unit , follow rehabilitation program . However , non fluent aphasic patient remain chronically handicap despite intensive logopedic training . The objective clinical project test action pharmacologic agent verbal fluency aphasic patient victim cerebral infarction . Only study do various pharmacologic agent , although result clearly conclusive , sufficiently positive suggest launch well control randomize cross-over study . Then objective study test action amantadine , DOPA-agonist , double blind cross-over trial , amantadine / placebo , verbal fluency chronic post stroke aphasic patient .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>RANKIN &lt; 3 &gt; 18 year &lt; 75 francophone within cognitive deficit know stroke stroke , single sylvian artery area aphasia `` non fluent `` follow stroke stroke &gt; six month stable treatment RANKIN &gt; 3 non francophone read write many stroke indication participate another clinical trial deaf blind intercurrent disease new treatment ( &lt; 2 month ) cognitive pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>cerebral infarction</keyword>
</DOC>